CDK2AP2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09469(CDK2AP2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The CDK2AP2 (Cyclin-Dependent Kinase 2-Associated Protein 2) antibody is a tool used to study the role of CDK2AP2. a protein implicated in cell cycle regulation and epigenetic modulation. CDK2AP2. also known as DOC-1R, shares homology with CDK2AP1 (DOC-1), a tumor suppressor involved in cell proliferation and differentiation. CDK2AP2 interacts with DNA methyltransferase 1 (DNMT1) and other epigenetic regulators, suggesting its role in DNA methylation and transcriptional repression. It is expressed in various tissues, including embryonic and adult stem cells, and is linked to developmental processes and tissue homeostasis.

Research using CDK2AP2 antibodies has focused on understanding its function in cancer biology, particularly in oral squamous cell carcinoma and colorectal cancer, where altered expression correlates with disease progression. The antibody enables detection of CDK2AP2 in Western blotting, immunohistochemistry, and immunofluorescence, aiding in studies of its subcellular localization and interactions. Additionally, CDK2AP2 is hypothesized to influence stem cell self-renewal and differentiation by modulating Wnt/β-catenin signaling, making it relevant in regenerative medicine.

Commercial CDK2AP2 antibodies are typically raised against specific epitopes, with validation in knockdown/knockout models to ensure specificity. Their development supports ongoing exploration of CDK2AP2 as a potential biomarker or therapeutic target in oncology and developmental disorders.